These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34638366)

  • 1. Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer.
    Simões Corrêa Galendi J; Vennedey V; Kentenich H; Stock S; Müller D
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease.
    Zhou T; Chen Z; Li H; Xie F
    Med Decis Making; 2021 Aug; 41(6):685-692. PubMed ID: 33813938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain.
    Moya-Alarcón C; González-Domínguez A; Simon S; Pérez-Román I; González-Martín A; Bayo-Lozano E; Sánchez-Heras AB
    Clin Transl Oncol; 2019 Aug; 21(8):1076-1084. PubMed ID: 30617925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
    Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
    J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the measurement of health utilities in published cost-utility analyses.
    Brauer CA; Rosen AB; Greenberg D; Neumann PJ
    Value Health; 2006; 9(4):213-8. PubMed ID: 16903990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of classic utilities to published pediatric cost-utility studies.
    Finnell SM; Carroll AE; Downs SM
    Acad Pediatr; 2012; 12(3):219-28. PubMed ID: 22075466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analyses of drug therapies in breast cancer: a systematic review.
    Nerich V; Saing S; Gamper EM; Kemmler G; Daval F; Pivot X; Holzner B
    Breast Cancer Res Treat; 2016 Oct; 159(3):407-24. PubMed ID: 27572551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health state utilities for metastatic breast cancer in Taiwan.
    Chou TC; Chiang SC; Ko Y
    Breast; 2020 Jun; 51():57-64. PubMed ID: 32213442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake Rates of Risk-Reducing Surgeries for Women at Increased Risk of Hereditary Breast and Ovarian Cancer Applied to Cost-Effectiveness Analyses: A Scoping Systematic Review.
    Simões Corrêa Galendi J; Kautz-Freimuth S; Stock S; Müller D
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review.
    Carter GC; King DT; Hess LM; Mitchell SA; Taipale KL; Kiiskinen U; Rajan N; Novick D; Liepa AM
    J Med Econ; 2015; 18(11):954-66. PubMed ID: 26212479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results.
    Zhou J; Millier A; François C; Aballéa S; Toumi M
    J Mark Access Health Policy; 2019; 7(1):1648973. PubMed ID: 31489150
    [No Abstract]   [Full Text] [Related]  

  • 12. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth and quality of the cost-utility literature, 1976-2001.
    Neumann PJ; Greenberg D; Olchanski NV; Stone PW; Rosen AB
    Value Health; 2005; 8(1):3-9. PubMed ID: 15841889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The State of Cost-Utility Analyses in Asia: A Systematic Review.
    Thorat T; Lin PJ; Neumann PJ
    Value Health Reg Issues; 2015 May; 6():7-13. PubMed ID: 29698196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing face of the cost-utility literature, 1990-2012.
    Neumann PJ; Thorat T; Shi J; Saret CJ; Cohen JT
    Value Health; 2015 Mar; 18(2):271-7. PubMed ID: 25773562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review.
    Koldehoff A; Danner M; Civello D; Rhiem K; Stock S; Müller D
    Value Health; 2021 Feb; 24(2):303-312. PubMed ID: 33518037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical appraisal of health-state utility values used in breast cancer-related cost-utility analyses.
    Nerich V; Saing S; Gamper EM; Holzner B; Pivot X; Viney R; Kemmler G
    Breast Cancer Res Treat; 2017 Aug; 164(3):527-536. PubMed ID: 28497177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can cost utility evaluations inform decision making about interventions for low back pain?
    Dagenais S; Roffey DM; Wai EK; Haldeman S; Caro J
    Spine J; 2009 Nov; 9(11):944-57. PubMed ID: 19748833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic overview of cost-utility assessments in oncology.
    Earle CC; Chapman RH; Baker CS; Bell CM; Stone PW; Sandberg EA; Neumann PJ
    J Clin Oncol; 2000 Sep; 18(18):3302-17. PubMed ID: 10986064
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.